BURLONE, MICHELA Emma
 Distribuzione geografica
Continente #
NA - Nord America 1.728
EU - Europa 1.699
AS - Asia 1.050
SA - Sud America 170
Continente sconosciuto - Info sul continente non disponibili 70
AF - Africa 30
OC - Oceania 1
Totale 4.748
Nazione #
US - Stati Uniti d'America 1.681
RU - Federazione Russa 419
SG - Singapore 306
IE - Irlanda 301
CN - Cina 253
DE - Germania 195
IT - Italia 188
SE - Svezia 145
FR - Francia 139
VN - Vietnam 137
BR - Brasile 131
HK - Hong Kong 128
UA - Ucraina 103
IN - India 85
GB - Regno Unito 54
FI - Finlandia 52
BD - Bangladesh 35
CA - Canada 31
KR - Corea 25
AT - Austria 24
AR - Argentina 18
ID - Indonesia 18
BE - Belgio 16
PL - Polonia 14
MX - Messico 13
ES - Italia 12
NL - Olanda 12
BJ - Benin 11
CZ - Repubblica Ceca 10
ZA - Sudafrica 9
TR - Turchia 8
EC - Ecuador 7
JP - Giappone 7
IQ - Iraq 6
IR - Iran 6
KE - Kenya 5
PH - Filippine 5
CH - Svizzera 4
SA - Arabia Saudita 4
VE - Venezuela 4
AZ - Azerbaigian 3
CL - Cile 3
JO - Giordania 3
PY - Paraguay 3
UZ - Uzbekistan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
EU - Europa 2
MY - Malesia 2
PE - Perù 2
PK - Pakistan 2
PT - Portogallo 2
SI - Slovenia 2
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CO - Colombia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MN - Mongolia 1
MT - Malta 1
NP - Nepal 1
PS - Palestinian Territory 1
RO - Romania 1
SN - Senegal 1
SO - Somalia 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
Totale 4.683
Città #
Dublin 298
San Jose 208
Jacksonville 177
Hong Kong 128
Ashburn 117
Singapore 109
Chandler 89
Dearborn 82
Beijing 79
Council Bluffs 75
Ann Arbor 67
Wilmington 54
Columbus 46
Los Angeles 44
Moscow 42
Piemonte 39
Ho Chi Minh City 37
Novara 36
Lauterbourg 34
Princeton 34
Santa Clara 34
Lawrence 33
Munich 33
Buffalo 28
Hanoi 28
Seoul 25
New York 23
São Paulo 21
Frankfurt am Main 18
San Mateo 18
Brussels 16
Milan 16
Andover 14
Nuremberg 13
Helsinki 12
Jakarta 12
Atlanta 11
Cotonou 11
Dallas 11
Houston 11
Phoenix 11
Brooklyn 10
Denver 10
Dong Ket 10
Toronto 10
Nanjing 9
Turin 9
Amsterdam 8
Brno 8
Falkenstein 8
Guangzhou 8
Hefei 8
Warsaw 8
Bremen 7
Da Nang 7
London 7
Mumbai 7
Orem 7
Rome 7
Seattle 7
Tianjin 7
Chicago 6
Hangzhou 6
Johannesburg 6
Poplar 6
Redondo Beach 6
Tokyo 6
Vienna 6
Ankara 5
Augusta 5
Bexley 5
Jinan 5
Kunming 5
Manchester 5
Montreal 5
Nairobi 5
Porto Alegre 5
Stockholm 5
Biên Hòa 4
Boardman 4
Boston 4
Curitiba 4
Dhaka 4
Hillsboro 4
Hải Dương 4
Leawood 4
Mexico City 4
Monmouth Junction 4
Norwalk 4
Rio de Janeiro 4
Shanghai 4
Turku 4
Woodbridge 4
Amman 3
Baku 3
Brasília 3
Calgary 3
Cassano Magnago 3
Charlotte 3
Chengdu 3
Totale 2.529
Nome #
Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment 169
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 165
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 160
Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients 155
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 143
17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon 142
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 137
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 137
Red cell distribution width and platelet count as biomarkers of pulmonary arterial hypertension in patients with connective tissue disorders 137
Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents 132
Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis 131
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 128
Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia 127
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy] 127
Influence of age on sex-related differences among patients with hepatitis C. 126
Liver stiffness, not fat liver content, predicts the length of QTc interval in patients with chronic liver disease 126
HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment 122
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 119
Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C 118
Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease 117
Recent advances in HCV entry 113
IL28B Polymorphism, Blood Interferon-alpha Concentration, and Disease Stage of HCV Mono-infected and HCV-HIV Co-infected Patients. 112
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 111
Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C 109
Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study. 108
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 107
Interferon-stimulated gene pathways in the treatment of viral hepatitis 103
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 100
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 99
Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C 98
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 98
Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study 95
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. 90
GENETIC POLYMORPHISM AT THE APOLIPOPROTEIN E LOCUS AFFECTS THE OUTCOME OF CHRONIC HEPATITIS B 89
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 83
Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development 83
Toxocara encephalitis presenting with autonomous nervous system involvement 82
From MASH to HCC: the role of Gas6/TAM receptors 78
Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression 72
PANCREATOBILIARY REFLUX RESULTING IN PANCREATIC ASCITES AND CHOLEPERITONEUM AFTER GALLBLADDER PERFORATION 70
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 66
Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis 64
Totale 4.748
Categoria #
all - tutte 22.067
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.067


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022230 0 13 31 18 15 2 20 12 16 22 32 49
2022/2023641 60 33 41 7 44 62 17 36 307 1 23 10
2023/2024240 24 39 21 0 35 2 42 6 1 4 27 39
2024/2025537 17 3 41 7 17 32 58 51 128 57 17 109
2025/20262.026 98 91 121 321 184 139 277 306 154 158 115 62
2026/2027180 61 119 0 0 0 0 0 0 0 0 0 0
Totale 4.748